Quanterix appointed Andrew Catalano as chief operating officer, bringing prior operations experience from Akoya Biosciences, which Quanterix acquired in 2025. In parallel, Verge Labs—formerly Verge Genomics—named Cara Leibowitz chief business officer, Emily Ripka VP of product and engineering, Yan Wu head of AI research, and Sean Hackett head of computational biology. In synthetic biology, Constructive Bio added Jim Weissman to its board of directors. Weissman previously held senior roles at Dicerna Pharmaceuticals, including executive VP, chief operating officer, and chief business officer. Taken together, the appointments signal an emphasis on scaling operations, commercial execution, and platform refinement across diagnostics, AI-enabled drug discovery, and synthetic biology.